Efficacy Evaluation Of Jiawei Yupingfeng San In Treating Diarrhea Irritable Bowel Syndrome With Deficiency Of Lung And Spleen

Objective:To observe the clinical efficacy,safety and recurrence of Jiawei Yupingfeng San in the treatment of Diarrhea Irritable Bowel Syndrome with deficiency of lung and spleen,and to provide clinical application basis for Jiawei Yupingfeng San to treat Diarrhea-type Irritable Bowel Syndrome(IBS).Methods:A total of 60 patients with Diarrhea-type Irritable Bowel Syndrome with deficiency of lung and spleen in the Department of Gastroenterology in Jiangsu Provincial Hospital of Traditional Chinese Medicine were collected and randomly divided into a treatment group and a control group,with 30 patients in each group.The treatment group was treated with Jiawei Yupingfeng San,and the control group was treated with pinaverium bromide.Both groups were treated for 4 weeks and followed up for 4 weeks.The efficacy,TCM symptoms,safety and recurrence of were compared between the two groups before and after treatment.Results:(1)Comparison of overall efficacy:After 4 weeks of treatment,the total effective rate in the treatment group was 96.7%,and in the control group was 56.7%.The difference between the groups was statistically significant(P<0.01).(2)Comparison of total TCM symptom scores:Within the group:the difference in total symptom scores at each time node after treatment and before treatment was statistically significant(P<0.01);Between the groups:At each time nodes after treatment,the difference in total TCM symptoms score was statistically significant(P<0.01).(3)Comparison of main symptoms scores:Within the group:The difference in the main symptom scores at each time node after treatment was significantly statistically significant(P<0.01);Between the groups:There was no significant difference in the main symptom scores between the two groups at week 2(P>0.05).At 4 and 8 weeks,the difference in the main symptom scores was statistically significant(P<0.01).(4)Comparison of secondary symptom scores:Within the group:The difference of the secondary symptom scores of the treatment group at each time node compared with that before treatment was statistically significant(P<0.01).The difference of the secondary symptom scores of the control group after 2 weeks and after 8 weeks had no significant difference(P>0.05),and after 4 weeks,the difference was statistically significant(P<0.05);Between the groups:At each time node,the difference of the secondary symptom scores was statistically significant(P<0.01).(5)Comparison of single symptom scores:Within the group:In the treatment group,the difference of single symptom scores before and after treatment was statistically significant(P<0.01);In the control group,there were no statistically significant difference in the scores of fatigue,spontaneous sweating and fear of wind before and after treatment(P>0.05);The remaining single symptom scores were significantly different(P<0.01);Between the groups:The difference in stool frequency after treatment was statistically significant(P<0.05),and the remaining single symptoms scores were significantly different(P<0.01).(6)Comparison of IBS-SSS:Within the group:The difference between IBS-SSS scores before and after treatment was statistically significant(P<0.01);Between the groups:The difference after treatment was statistically significant(P<0.01).(7)Comparison of recurrence rates:The recurrence rate in the treatment group was 3.4%,and in the control group was 41.2%.The difference in recurrence rate between the groups was statistically significant(P<0.01).Research conclusion:Jiawei Yupingfeng San has obvious advantages in improving clinical efficacy,reducing the severity of symptoms and recurrence in treating Diarrhea-type Irritable Bowel Syndrome with deficiency of the lung and spleen,and it is highly safe.It is worthy of further research and promotion in clinical.